Dr Delphine Larrieu


Delphine Larrieu
Delphine Larrieu

Dr Delphine Larrieu is an Assistant Professor in the Department of Pharmacology.

After completing her PhD in Molecular Biology at the University of Grenoble, France, Dr Larrieu joined the University of Cambridge in 2011 as a postdoctoral fellow in Prof Steve Jackson laboratory.

Since then, her research has focused on rare premature ageing diseases (Progerias) caused by mutations affecting the integrity of the cell nucleus. Upon being awarded a Wellcome Trust Sir Henry Dale fellowship in 2017, Dr Larrieu set up her own lab at the Cambridge Institute for Medical Research (CIMR) where she investigated the molecular mechanisms behind Progerias and set up whole genome CRISPR screens to identify new therapeutic strategies for these diseases.

In 2022, she was appointed as an Assistant Professor in Pharmacology where she is teaching the Biology of Ageing to Part II students.

Dr Larrieu also has a strong interest in translational research. In 2020, she co-founded Adrestia Therapeutics, whose aim is to restore the biological balance in disease. She is also a scientific advisor for Shift Bioscience, whose mission is to discover new cellular rejuvenation pathways.

Research Interests

Cellular mechanisms of ageing

Premature ageing disorders

Nuclear Envelope

Link to website


Links to online publications, articles or other work

Key publications 

  • The BAF A12T mutation disrupts lamin A/C interaction, impairing robust repair of nuclear envelope ruptures in Nestor–Guillermo progeria syndrome cells. Anne F. J. Janssen, Agathe Marcelot, Sophia Y. Breusegem, Pierre Legrand, Sophie Zinn-Justin and Delphine Larrieu Nucleic Acids Research, Aug 2022, gkac726
  • Current Methods and Pipelines for Image-Based Quantitation of Nuclear Shape and Nuclear Envelope Abnormalities. Anne F. J. Janssen, Sophia Y. Breusegem and Delphine Larrieu. Cells, Jan 2022, 11(3), 347; 2019
  • Abnormal microtubule dynamics disrupt nucleocytoplasmic transport in tau-mediated frontotemporal dementia. Francesco Paonessa, Lewis Evans, Ravi Solanki, Delphine Larrieu, Selina Wray, John Hardy, Stephen P Jackson, Frederick J Livesey. Cell Reports, Jan 2019 P582-593.E5
  • Inhibition of acetyltransferase NAT10 normalizes progeric and aging cells by rebalancing the Transportin-1 nuclear import pathway. Delphine Larrieu*, Emmanuelle Viré, Samuel Robson, Sophia Y. Breusegem, Tony Kouzarides and Stephen P. Jackson*. * Co-corresponding. Sci Signal. 2018 Jul 3;11(537).
  • Targeting of NAT10 enhances healthspan in a mouse model of human accelerated aging syndrome. Gabriel Balmus*, Delphine Larrieu*#, Ana C Barros, Casey Collins, Monica Abrudan, Mukerrem Demir, Nicola J Geisler, Christopher J. Lelliott, Jacqueline K. White, Natasha A Karp, James Atkinson, Andrea Kirton, Matt Jacobsen, Dean Clift, Raphael Rodriguez, Sanger Mouse Genetics Project, David J Adams, Stephen P Jackson#. *Co-authorship, #Co-corresponding. Nat Commun. 2018 Apr 27;9(1):1700.
  • A novel somatic mutation achieves partial rescue in a child with Hutchinson-Gilford progeria syndrome. Bar DZ, Arlt MF, Brazier JF, Norris WE, Campbell SE, Chines P, Larrieu D, Jackson SP, Collins FS, Glover TW, Gordon LB. J Med Genet. 2017 Mar;54(3):212-216.
  • Prelamin A impairs 53BP1 nuclear entry by mislocalizing NUP153 and disrupting the Ran gradient. Cobb AM, Larrieu D, Warren DT, Liu Y, Srivastava S, Smith AJ, Bowater RP, Jackson SP, Shanahan CM. Aging Cell. 2016 Jul 27
  • CRISPR-Cas9D10A nickase-based genotypic and phenotypic screening to enhance genome editing. W Chiang*, C le Sage*, D Larrieu, M Demir and Stephen P. Jackson. Sci Rep. 2016 Apr 15;6:24356.
  • Chemical inhibition of NAT10 corrects defects of laminopathic cells. Larrieu D, Britton S, Demir M, Rodriguez R, Jackson SP. Science. 2014 May 2;344(6183):527-32